Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 21 publications
Pharmacokinetics, mass balance and metabolic profiling of resmetirom in healthy subjects and nonclinical metabolism and disposition.
Journal: Xenobiotica; the fate of foreign compounds in biological systems
Published: June 10, 2026
Self-Reported Cognitive Function in Metabolic Dysfunction-associated Steatotic Liver Disease and Metabolic Dysfunction-associated Steatohepatitis: A Post-hoc Analysis of the MAESTRO Resmetirom Trials.
Journal: Journal of clinical and experimental hepatology
Published: October 21, 2025
Improvement in health-related quality of life after treatment with resmetirom in patients with the spectrum of MASLD: From early MASH to MASH cirrhosis.
Journal: Hepatology communications
Published: October 06, 2025
Effects of Resmetirom on Metabolic-Dysfunction Associated Steatohepatitis in Patients With Weight Loss and/or Diabetes Taking Glucagon-Like Peptide-1 Receptor Agonists and Other Diabetes Therapies: A Secondary Analysis of the MAESTRO-NASH Trial.
Journal: Alimentary pharmacology & therapeutics
Published: July 18, 2025
Quantitative regression of qFibrosis with resmetirom: Exploratory histologic endpoints from the MAESTRO-NASH phase III clinical trial.
Journal: Journal of hepatology
Published: July 14, 2025
The Cholate Challenge Test Quantified Baseline Functional Heterogeneity and Improvement in Response to Resmetirom in MASH-related Child-Pugh A Cirrhosis.
Journal: Gastro hep advances
Published: July 09, 2025
Assessments of Health Utilities in Patients With Metabolic Dysfunction-Associated Steatohepatitis: Cross-Walk Between Disease-Specific Chronic Liver Disease Questionnaire, Short Form SF-6D, and EuroQol EQ-5D Instruments.
Journal: Gastro hep advances
Published: September 24, 2024
Health-related quality of life (HRQL) assessments in a 52-week, double-blind, randomized, placebo-controlled phase III study of resmetirom (MGL-3196) in patients with metabolic dysfunction-associated steatohepatitis (MASH) and fibrosis.
Journal: Hepatology (Baltimore, Md.)
Published: June 19, 2024
A Phase 3 Trial of Resmetirom in NASH with Liver Fibrosis. Reply.
Journal: The New England journal of medicine
Published: May 01, 2024
A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis.
Journal: The New England journal of medicine
Published: February 07, 2024
Design of the phase 3 MAESTRO clinical program to evaluate resmetirom for the treatment of nonalcoholic steatohepatitis.
Journal: Alimentary pharmacology & therapeutics
Published: August 15, 2023
Last Updated: 09/26/2026